![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Ertugliflozin.svg/640px-Ertugliflozin.svg.png&w=640&q=50)
Ertugliflozin
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Ertugliflozin?
Summarize this article for a 10 year old
Ertugliflozin, sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes.[3][4]
![]() | |
Clinical data | |
---|---|
Trade names | Steglatro |
Other names | PF-04971729, ertugliflozin l-pyroglutamic acid |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Antidiabetic agent |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~100% |
Protein binding | 93.6% |
Metabolism | UGT1A9, UGT2B7 |
Metabolites | Glucuronides |
Elimination half-life | ~17 hours |
Excretion | 41% faeces, 50% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.237.989 ![]() |
Chemical and physical data | |
Formula | C22H25ClO7 |
Molar mass | 436.89 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects include fungal infections of the vagina and other infections of the female reproductive system.[4]
Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor[3][4] and is in the class of drugs known as gliflozins.[5]
In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin.[6] In the European Union, it was approved in March 2018, for use as a monotherapy or combination therapy.[7] In September 2020, The New England Journal of Medicine reported that ertugliflozin was shown to be essentially non-inferior to placebo with respect to cardiovascular events.[8]
A combination with metformin is marketed as Segluromet and a combination with sitagliptin is marketed as Steglujan.[1][9][10][11][12]